Search Results
Phase II study of ANX005 in patients with Huntington’s disease
Phase II study investigating ANX005 in Huntington’s disease
Rajeev Kumar, MDS 2022: ANX005, a humanized mAb for Huntington’s disease, the phase 2 study results
Insights into a Phase II study evaluating ANX005 in wAIHA
KINECT-HD Phase III study results: valbenazine for chorea associated with Huntington’s disease
RESEARCH WEBINAR: ANNEXON BIOSCIENCES
2021 Huntington's Disease Research Updates
Update on huntingtin-lowering strategies under investigation for Huntington’s disease
2022 Annual Huntington's Disease Symposium | Research Update
Introduction to Annexon Biosciences and ANX005 HD 02 Study
Jenny Townhill | Huntington's disease conference
Huntingtons disease: a clinical review | RTCL.TV
